Elsevier

Atherosclerosis

Volume 170, Issue 1, September 2003, Pages 1-9
Atherosclerosis

Review
Lipoprotein lipase and atherosclerosis

https://doi.org/10.1016/S0021-9150(03)00014-5Get rights and content

Abstract

Lipoprotein lipase (LPL) is a key enzyme in catabolism of plasma lipoprotein triglycerides (TGs), and in that capacity has a salutary influence on plasma HDL, and thus appears to be antiatherogenic. However, the non-catalytic functions of LPL, such as lipoprotein bridging and selective uptake of lipoprotein cholesteryl ester, are regarded as proatherogenic. The balance between the pro and antiatherogenic attributes of LPL is evaluated on the basis of recent evidence derived from transgenic animals and from studies of common LPL mutations in man. This review also includes recently accrued information on the role of nuclear receptors and their ligands and agonists in regulation of LPL in various organs. The studies reviewed are not only of academic interest, but may also have practical applications in development of agents that may regulate LPL activity in humans.

Introduction

Lipoprotein lipase (LPL) is a key enzyme in hydrolysis of chylomicron and very low density lipoprotein (VLDL) triglyceride (TG). The LPL gene is about 35 kb in length, contains ten exons, and is mapped to chromosome 8p22 [1]. The released fatty acids are taken up mainly by the heart, skeletal muscle and adipose tissue. These organs are the principal sites of LPL synthesis, but in the heart it occurs mainly not in the cardiac myocytes but rather in interstitial ‘mesenchymal cells’ [2]. This was documented by in situ hybridization, which showed that the highest concentration of LPL mRNA is seen in these cells [3]. Apart from its lipolytic activity, LPL in cell cultures acts also as a cholesteryl ester transferase into cells, a process that is not linked to the catalytic activity of the enzyme and is dissociated from the uptake of the protein moiety of lipoproteins [4], [5]. The LPL-mediated selective uptake of lipoprotein cholesteryl ester occurs also in vivo, as exemplified by uptake of cholesteryl linoleyl ether by the lactating mammary gland after injection of labeled chylomicrons [6].

The transferase activity of LPL induced the enrichment of aortic smooth muscle cells (SMC) exposed to cholesteryl oleate, and these results suggested that, in the aortic wall, LPL could play a role in cholesteryl ester accretion in SMC that occurs during atherogenesis [7]. Within the wall of the atherosclerotic artery, LPL is derived mainly from macrophages and SMC [8], [9], [10], and studies in cell culture have demonstrated its regulation by various cytokines [11]. A revival in the interest in the role LPL plays in atherosclerosis occurred in the mid nineties and the highlights of this field of research had been admirably reviewed [11], [12], [13], [14], [15]. In this review we shall focus on the evaluation of the balance between the pro and antiatherogenic properties of LPL in experimental animals as well as in humans. The frequent mutations in the LPL gene, which have been recently described in various populations, will provide the basis for the discussion of the putative link between LPL and coronary heart disease (CHD).

Section snippets

Proatherogenic role of macrophage LPL

Zilversmit was the first to propose that chylomicron and VLDL remnants formed by endothelial LPL may contribute to the development of atherosclerosis [16]. While the above mentioned mechanism stressed the putative role of endothelial surface bound LPL, subsequent research was directed also towards elucidation of the involvement of macrophage LPL in this process. Thus, fetal hepatic cells obtained from donors homozygous for LPL−/− or LPL+/+ were injected into irradiated mice, and atherosclerosis

Role of LPL in lipoprotein bridging and selective CE uptake

An important facet of potential proatherogenic activity of LPL is linked to its capacity to enhance binding of lipoproteins to cellular receptors, such as LRP [26], and to heparan sulfate on cell surfaces and extracellular matrix [27], [28]. This subject was dealt with extensively in a recent review [15]; we shall discuss the aspect of LPL mediated selective cellular uptake of cholesteryl ester from lipoproteins. The synthesis of an unhydrolyzable analog of cholesteryl ester, namely cholesteryl

Antiatherogenic effects of LPL

The first studies on the atheroprotective effect of plasma LPL were performed on mice overexpressing hLPL [42], [43]. In the LDL-R−/− mice overexpressing hLPL, plasma cholesterol and TG levels were lower by 40 and 90%, respectively, than in LDL-R−/− controls [42]. Atherosclerosis was found to be reduced 18-fold in the LPL overexpressing mice, which was most likely due to the lower plasma lipid levels [42]. In apoE−/− mice overexpressing hLPL, fed an atherogenic diet, plasma total cholesterol

Regulation of LPL by PPAR's, RXR and LXR

Peroxisome proliferator-activated receptors (PPARs) are ligand-activated transcription factors, which, when heterodimerized with the retinoic acid receptor (RXR), bind to a specific peroxisome-proliferator response element, and regulate expression of target genes active in lipid metabolism [47]; this element has been identified in the hLPL promoter [48]. Cultured adult rat cardiomyocytes were treated with synthetic or natural PPAR-α ligands and after 16 h, cellular and heparin releasable LPL

LPL mutations and CHD

During the last decade, interest was reawakened in the relationship between LPL and atherosclerosis in humans. Three common LPL mutations—N291S, D9N and S447X, that occur at a relatively high frequency, enabled investigators to look for the link between LPL genetic variation and CHD. The D9N mutation is due to a change of aspartate residue to asparagine, the N291S is due to an asparagine to serine change, and the S447X is due to a premature stop codon, with the loss of serine and lysine

Concluding remarks

The data obtained from studies in transgenic animals demonstrate the involvement of LPL in atherosclerosis. The atheroprotective role of plasma LPL is well documented, and the mode of operation is linked to its catalytic activity, resulting in decrease in plasma TG and increase in HDL-C. On the other hand, the mechanism by which macrophage LPL enhances atherosclerosis is more complex as it involves also the noncatalytic activity of the enzyme on lipoproteins, such as bridging and selective

Addendum

During the time this manuscript was under review, three reviews on LPL were published emphasizing the renewed interest in this subject [83], [84], [85].

Acknowledgements

We do acknowledge the invaluable comments and suggesions of Professor Y. Friedlander, especially with regard to the section dealing with mutations. Our thanks are extended to N. Kellman for her indefatigable help and patience in the preparation of the manuscript for publication.

References (85)

  • M.C. Beauchamp et al.

    Macrophage lipoprotein lipase expression is increased in patients with heterozygous familial hypercholesterolemia

    J. Lipid Res.

    (2002)
  • J.E. Corey et al.

    Effect of cholesterol feeding on arterial lipolytic activity in the rabbit

    Atherosclerosis

    (1977)
  • J.P. Werba et al.

    Marked neointimal lipoprotein lipase increase in distinct models of proclivity to atherosclerosis: a feature independent of endothelial layer integrity

    Atherosclerosis

    (2001)
  • I. Tabas et al.

    Lipoprotein lipase and sphingomyelinase synergistically enhance the association of atherogenic lipoproteins with smooth muscle cells and extracellular matrix. A possible mechanism for low density lipoprotein and lipoprotein(a) retention and macrophage foam cell formation

    J. Biol. Chem.

    (1993)
  • O. Stein et al.

    Biological labeling of very low density lipoproteins with cholesteryl linoleyl ether and its fate in the intact rat

    Biochim. Biophys. Acta

    (1980)
  • Y. Stein et al.

    M Metabolism of HDL-cholesteryl ester in the rat, studied with a nonhydrolyzable analog, cholesteryl linoleyl ether

    Biochim. Biophys. Acta

    (1983)
  • T. Chajek-Shaul et al.

    Binding of lipoprotein lipase to the cell surface is essential for the transmembrane transport of chylomicron cholesteryl ester

    Biochim. Biophys. Acta

    (1982)
  • O. Stein et al.

    Transfer of cholesteryl linoleyl ether from phosphatidylcholine and phosphatidylethanolamine liposomes to cultured cells catalyzed by lipoprotein lipase

    Biochim. Biophys. Acta

    (1983)
  • T. Seo et al.

    Lipoprotein lipase-mediated selective uptake from low density lipoprotein requires cell surface proteoglycans and is independent of scavenger receptor class B type 1

    J. Biol. Chem.

    (2000)
  • E. Leitersdorf et al.

    Uptake of rat plasma HDL subfractions labeled with [3H]cholesteryl linoleyl ether or with 125I by cultured rat hepatocytes and adrenal cells

    Biochim. Biophys. Acta

    (1984)
  • C. Glass et al.

    Uptake of high-density lipoprotein-associated apoprotein A-l and cholesterol esters by 16 tissues of the rat in vivo and by adrenal cells and hepatocytes in vitro

    J. Biol. Chem.

    (1985)
  • A. Israeli et al.

    Preferential binding of [3H]cholesteryl linoleyl ether-HDL3 by bovine adrenal membranes

    Biochim. Biophys. Acta

    (1987)
  • F. Rinninger et al.

    Lipoprotein lipase mediates an increase in the selective uptake of high density lipoprotein-associated cholesteryl esters by hepatic cells in culture

    J. Lipid Res.

    (1998)
  • F. Rinninger et al.

    Lipoprotein lipase mediates an increase in selective uptake of HDL-associated cholesteryl esters by cells in culture independent of scavenger receptor BI

    J. Lipid Res.

    (2001)
  • M. Merkel et al.

    Inactive lipoprotein lipase (LPL) alone increases selective cholesterol ester uptake in vivo, whereas in the presence of active LPL it also increases triglyceride hydrolysis and whole particle lipoprotein uptake

    J. Biol. Chem.

    (2002)
  • H. Yagyu et al.

    Overexpressed lipoprotein lipase protects against atherosclerosis in apolipoprotein E knockout mice

    J. Lipid Res.

    (1999)
  • J. Fan et al.

    Overexpression of lipoprotein lipase in transgenic rabbits inhibits diet-induced hypercholesterolemia and atherosclerosis

    J. Biol. Chem.

    (2001)
  • F.G. Gbaguidi et al.

    Peroxisome proliferator-activated receptor (PPAR) agonists decrease lipoprotein lipase secretion and glycated LDL uptake by human macrophages

    FEBS Lett.

    (2002)
  • L. Li et al.

    Peroxisome proliferator-activated receptor alpha and gamma agonists upregulate human macrophage lipoprotein lipase expression

    Atherosclerosis

    (2002)
  • Y. Zhang et al.

    Regulation of lipoprotein lipase by the oxysterol receptors, LXRα and LXRβ

    J. Biol. Chem.

    (2001)
  • V. Murthy et al.

    Molecular pathobiology of the human lipoprotein lipase gene

    Pharmacol. Ther.

    (1996)
  • W. Chen et al.

    Influence of lipoprotein lipase serine 447 stop polymorphism on tracking of triglycerides and HDL cholesterol from childhood to adulthood and familial risk of coronary artery disease: the Bogalusa heart study

    Atherosclerosis

    (2001)
  • P.J. Talmud et al.

    Substitution of asparagine for aspartic acid at residue 9 (D9N) of lipoprotein lipase markedly augments risk of ischaemic heart disease in male smokers

    Atherosclerosis

    (2000)
  • J.M. Ordovas et al.

    Gene-diet interaction in determining plasma lipid response to dietary intervention

    Atherosclerosis

    (1995)
  • Y. Friedlander et al.

    The contribution of candidate genes to the response of plasma lipids and lipoproteins to dietary challenge

    Atherosclerosis

    (2000)
  • F.M. van Bockxmeer et al.

    Lipoprotein lipase D9N, N291S and S447X polymorphisms: their influence on premature coronary heart disease and plasma lipids

    Atherosclerosis

    (2001)
  • S.H. McGladdery et al.

    Common mutations in the lipoprotein lipase gene (LPL); effects on HDL-cholesterol levels in a Chinese Canadian population

    Atherosclerosis

    (2001)
  • R.M. Fisher et al.

    Common variation in the lipoprotein lipase gene; effects on plasma lipids and risk of atherosclerosis

    Atherosclerosis

    (1997)
  • H. Zhang et al.

    Common sequence variants of lipoprotein lipase: standardized studies of in vitro expression and catalytic function

    Biochim. Biophys. Acta

    (1996)
  • S.S. Deeb et al.

    Structure of the human lipoprotein lipase gene

    Biochemistry

    (1989)
  • O. Stein et al.

    Expression of lipoprotein lipase mRNA in rat heart is localized mainly to mesenchymal cells as studied by in-situ hybridization

    Arterioscler. Thromb.

    (1991)
  • O. Stein et al.

    Can lipoprotein lipase be the culprit in cholesteryl ester accretion in smooth muscle cells in atheroma

    Atherosclerosis

    (1993)
  • Cited by (75)

    • Ibrolipim attenuates early-stage nephropathy in diet-induced diabetic minipigs: Focus on oxidative stress and fibrogenesis

      2020, Biomedicine and Pharmacotherapy
      Citation Excerpt :

      Hence, inhibition of these pathophysiological pathways may ameliorate DN and its aggravation to ESRD. Lipoprotein lipase (LPL) has been proved to play a crucial role in lipid metabolism by multifunctional actions such as hydrolysis of triglyceride-rich lipoproteins, bridged binding of lipoproteins to specific cell surface proteins, selective uptake of cholesteryl ester from lipoproteins, and the ability to stimulate cellular proliferation [8,9]. In the kidney, LPL is expressed by mesangial and / or tubular epithelial cells, and localizes to the vascular endothelium in the glomeruli [10–12].

    • Lipids

      2020, Present Knowledge in Nutrition: Basic Nutrition and Metabolism
    • The function of heparanase in diabetes and its complications

      2013, Canadian Journal of Diabetes
      Citation Excerpt :

      Interestingly, Goldberg's (42) study reported that endothelial-secreted heparanase promoted LPL transfer from adipocytes to the luminal endothelial surface in a co-culture system. Because LPL is not only a rate-limiting enzyme in the hydrolysis of circulating triglyceride (TG)-rich lipoproteins to release free FA, but also mediates a noncatalytic bridging function allowing simultaneous binding to both lipoproteins and specific cell surface proteins, it could facilitate cellular uptake of lipoproteins, such as LDL, and hence atherosclerosis (46). The central basis for heart failure in patients with diabetes is coronary disease associated with atherosclerosis.

    View all citing articles on Scopus
    View full text